Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells 16,083 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 16,083 shares of the company’s stock in a transaction dated Wednesday, September 23rd. The shares were sold at an average price of $628.64, for a total transaction of $10,110,417.12. Following the completion of the sale, the chief executive officer directly owned 417,289 shares of the company’s stock, valued at $262,324,556.96. This represents a 3.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Medpace Trading Down 0.3%

Medpace stock traded down $1.71 during mid-day trading on Friday, hitting $618.88. The company’s stock had a trading volume of 229,012 shares, compared to its average volume of 332,429. The stock’s fifty day moving average is $593.03 and its two-hundred day moving average is $515.26. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The firm has a market capitalization of $17.27 billion, a PE ratio of 36.28, a price-to-earnings-growth ratio of 2.81 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s quarterly revenue was up 17.2% on a year-over-year basis. During the same period last year, the business posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on MEDP shares. Leerink Partners set a $620.00 price target on Medpace in a report on Thursday, July 23rd. TD Cowen raised their price target on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Robert W. Baird boosted their price objective on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. BMO Capital Markets lifted their price objective on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Finally, Jefferies Financial Group reaffirmed a “hold” rating on shares of Medpace in a research note on Monday, September 14th. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $595.20.

Institutional Trading of Medpace

Institutional investors have recently added to or reduced their stakes in the stock. Schulhoff & Co. Inc. increased its stake in shares of Medpace by 1.1% during the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock worth $1,237,000 after purchasing an additional 25 shares in the last quarter. Balefire LLC lifted its holdings in Medpace by 6.1% in the 1st quarter. Balefire LLC now owns 451 shares of the company’s stock valued at $217,000 after purchasing an additional 26 shares in the last quarter. Root Financial Partners LLC boosted its stake in shares of Medpace by 34.1% during the 1st quarter. Root Financial Partners LLC now owns 122 shares of the company’s stock worth $59,000 after purchasing an additional 31 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Medpace by 2.8% during the second quarter. GAMMA Investing LLC now owns 1,158 shares of the company’s stock valued at $613,000 after buying an additional 32 shares during the period. Finally, Handelsbanken Fonder AB grew its stake in Medpace by 0.6% in the 2nd quarter. Handelsbanken Fonder AB now owns 7,020 shares of the company’s stock worth $3,718,000 after acquiring an additional 40 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.